Sign up to save your podcasts
Or
Share Tulisokibart, a New Drug for Moderate-to-Severe UC That May Come With Personalized Medicine
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Tulisokibart, a New Drug for Moderate-to-Severe UC That May Come With Personalized Medicine
Ellen Axenfeld, MD and Elie Al Zazzi, MD, MPH discuss "Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis,” by Sands BE, Feagan BG, Peyrin-Biroulet L, et al and the ARTEMIS-UC Study Group. Published in N Engl J Med. 2024 Sep 26;391(12):1119-1129.
View all episodes
By American College of Gastroenterology
4.7
1717 ratings
Ellen Axenfeld, MD and Elie Al Zazzi, MD, MPH discuss "Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis,” by Sands BE, Feagan BG, Peyrin-Biroulet L, et al and the ARTEMIS-UC Study Group. Published in N Engl J Med. 2024 Sep 26;391(12):1119-1129.
More shows like Evidence-Based GI: An ACG Publication and Podcast
View all
JAMA Clinical Reviews
497 Listeners
American Journal of Gastroenterology Author Podcasts
69 Listeners
Gut Podcast
8 Listeners
White Coat Investor Podcast
2,442 Listeners
The Curbsiders Internal Medicine Podcast
3,342 Listeners
Core IM | Internal Medicine Podcast
1,153 Listeners
Annals On Call Podcast
194 Listeners
The Clinical Problem Solvers
513 Listeners
Run the List
248 Listeners
Behind the Case: An ACG Case Reports Journal Podcast
6 Listeners
The Daily Motivation
914 Listeners
Critical Care Time
232 Listeners
Gastroenterology Learning Network
13 Listeners
Listen In: GI Endoscopy
33 Listeners
Gastroenterology & Endoscopy
3 Listeners